In this provocative commentary, we consider several questions posed by the late chronic
myeloid leukaemia (CML) expert Prof. Michele Baccarani, which he challenged us to …

The therapeutic landscape for chronic myeloid leukemia (CML) has improved significantly
with the approval of tyrosine kinase inhibitors (TKIs) for therapeutic use. Most patients with …

Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has
become part of routine care for patients with a sustained deep molecular response (DMR) …

Background Treatment‐free remission (TFR) has become the main target for chronic
myeloid leukemia (CML). Tyrosine kinase inhibitors (TKI) dose optimization is crucial in …

The introduction of tyrosine kinase inhibitors has considerably improved the life expectancy
(LE) for patients with chronic myeloid leukemia (CML). Evaluating health‐related quality of …

Background: In clinical studies, some patients who achieve deep molecular response (DMR)
can successfully discontinue tyrosine kinase inhibitor (TKI). TKI dose reduction is also an …

Over the last two decades, the introduction of targeted therapies and the advances in the
detection of BCR: ABL1 oncogene have dramatically improved comprehensive care for …

Chronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic
disorder that can be treated with targeted drugs and allows survival expectations …

OBJECTIVE: Cardiovascular system health becomes important with the extended survival of
chronic myeloid leukemia (CML) patients. Cardiotoxicities are related to the second-and …

Chronic myeloid leukemia (CML) in childhood represents only 3% of newly diagnosed
pediatric leukemia. The diagnostic hallmark of CML is the Philadelphia (Ph) chromosome …